Neuronetics Overview
- Year Founded
-
2001
- Status
-
Public
- Employees
-
211
- Stock Symbol
-
STIM
- Share Price
-
$2.03
- (As of Friday Closing)
Neuronetics General Information
Description
Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.
Contact Information
- 3222 Phoenixville Pike
- Malvern, PA 19355
- United States
Neuronetics Timeline
Neuronetics Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.03 | $1.82 | $1.03 - $6.95 | $58.7M | 28.9M | 79.3K | -$1.17 |
Neuronetics Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
|---|---|---|---|---|
| EV | 32,212 | 151,128 | 54,567 | 196,815 |
| Revenue | 69,232 | 65,206 | 55,312 | 49,244 |
| EBITDA | (29,803) | (34,860) | (29,374) | (25,890) |
| Net Income | (33,102) | (37,159) | (31,193) | (27,453) |
| Total Assets | 92,988 | 116,884 | 141,223 | 78,657 |
| Total Debt | 40,197 | 39,745 | 39,544 | 38,335 |
Neuronetics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Neuronetics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Neuronetics Comparisons
Industry
Financing
Details
000000
000000
Neuronetics Competitors (11)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Inspire Medical Systems | Formerly VC-backed | Golden Valley, MN | 000 | 00000 | 00000000 | 00000 |
| 0000000 | Private Equity-Backed | Pompano Beach, FL | 000 | 0000 | 000000000000 | 0000 |
| 0000000000 | Corporation | Farum, Denmark | 00 | |||
| 000000000 | Venture Capital-Backed | Milan, Italy | 00 | 000.00 | 0000000000 | 000.00 |
| 0000 000000000000 | Venture Capital-Backed | Malmö, Sweden | 00 | 000.00 | 00000000000 | 000.00 |
Neuronetics Patents
Neuronetics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20210228898-A1 | Magnetic stimulation coils and ferromagnetic components for treatment and diagnostic procedures | Pending | 20-Feb-2018 | 00000000 | 0 |
| EP-3755422-A4 | Magnetic stimulation coils and ferromagnetic components for treatment and diagnostic procedures | Pending | 20-Feb-2018 | 000000000 | 0 |
| EP-3755422-A1 | Magnetic stimulation coils and ferromagnetic components for treatment and diagnostic procedures | Pending | 20-Feb-2018 | 000000000 | |
| JP-2023055812-A | Magnetic stimulation coils and ferromagnetic components for therapeutic and diagnostic procedures | Pending | 20-Feb-2018 | 000000000 | |
| US-11000693-B2 | Magnetic stimulation coils and ferromagnetic components for treatment and diagnostic procedures | Active | 20-Feb-2018 | A61N2/02 | 00 |
Neuronetics Executive Team (33)
Neuronetics Board Members (25)
| Name | Representing | Role | Since |
|---|---|---|---|
| Brian Farley | Neuronetics | Chairman & Board Member | 000 0000 |
| Bruce Shook | Neuronetics | Board Member | 000 0000 |
| Glenn Muir MD | Neuronetics | Board Member | 000 0000 |
| John Bakewell | Self | Board Member | 000 0000 |
| Joseph Capper | Self | Board Member | 000 0000 |
Neuronetics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Neuronetics ESG
Risk Overview
Risk Rating
Updated April, 01, 2022
43.31 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 14,912
Rank
Percentile
Healthcare
Industry
00 of 616
Rank
Percentile
Medical Devices
Subindustry
00 of 221
Rank
Percentile
